Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Manifestations and Genetic Findings in Three Patients with Chediak-Higashi Syndrome: Highlighting the Splice Site Variants.

Iranian journal of allergy, asthma, and immunology·2026
Same author

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression.

EMBO molecular medicine·2026
Same author

Human LFA-1 governs T cell immune surveillance of the skin.

Science immunology·2026
Same author

Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanisms.

eLife·2026
Same author

Structure-Activity Relationship and Crystallographic Study of New Monobactams.

Journal of medicinal chemistry·2026
Same author

Structural and Dynamics Analyses of β-Lactam Inhibition of <i><i>Streptococcus pneumoniae</i></i> Penicillin-Binding Protein 1b (PBP1b) Guide Interrogation of Structure-Activity Relationships.

ACS chemical biology·2026

Related Experiment Video

Updated: Jul 9, 2026

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Common alterations in PBP1a from resistant Streptococcus pneumoniae decrease its reactivity toward beta-lactams:

Viviana Job1, Raphaël Carapito, Thierry Vernet

  • 1Laboratoire des Protéines Membranaires, Institut de Biologie Structurale Jean-Pierre Ebel, Université Joseph Fourier, UMR 5075-CNRS, CEA Grenoble, France.

The Journal of Biological Chemistry
|December 7, 2007
PubMed
Summary

High-level beta-lactam resistance in Streptococcus pneumoniae involves altered PBP1a. Structural analysis reveals a narrower active site cavity and reoriented catalytic residue in resistant strains, impacting drug efficacy.

More Related Videos

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Related Experiment Videos

Last Updated: Jul 9, 2026

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
08:53

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092

Published on: October 2, 2017

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Area of Science:

  • Microbiology
  • Structural Biology
  • Drug Resistance

Background:

  • Penicillin-binding proteins (PBPs) are crucial targets for beta-lactam antibiotics.
  • High-level beta-lactam resistance in Streptococcus pneumoniae necessitates alterations in multiple PBPs, including PBP1a, PBP2b, and PBP2x.

Purpose of the Study:

  • To elucidate the structural basis of high-level beta-lactam resistance in Streptococcus pneumoniae.
  • To investigate the role of specific mutations in PBP1a on beta-lactam resistance.

Main Methods:

  • Crystal structure determination of soluble PBP1a from a resistant strain (S. pneumoniae 5204).
  • Site-directed mutagenesis to introduce specific PBP1a mutations (T371A and TSQF(574-577)NTGY).
  • In vitro kinetic analysis and in vivo resistance measurements.

Main Results:

  • The crystal structure of PBP1a from resistant S. pneumoniae 5204 revealed a narrower, discontinuous active site cavity compared to susceptible strains.
  • A reorientation of the catalytic residue Ser370 was observed in the resistant PBP1a structure.
  • Investigated mutations (T371A and TSQF(574-577)NTGY) showed altered reaction kinetics and affected resistance levels.

Conclusions:

  • Structural modifications in PBP1a contribute significantly to high-level beta-lactam resistance in Streptococcus pneumoniae.
  • The altered active site cavity and catalytic residue reorientation are key factors in reduced antibiotic susceptibility.